Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Chat with Yara.AI
Your financial questions, answered anytime, instantly.
Cibil Report
Get cibil report
Do not call
En
Anuh Pharma Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Low
₹82.00
High
₹83.89
Price Summary
| Previous Close | ₹82.79 |
|---|---|
| Day's Range | ₹82.00 - ₹83.89 |
| Open | ₹82.00 |
| 52 Week Range | ₹67.00 - ₹99.50 |
| Volume | 17,515 |
| Market Cap | ₹0.00 |
| Previous Close | ₹82.57 |
|---|---|
| Day's Range | ₹80.98 - ₹84.00 |
| Open | ₹82.27 |
| 52 Week Range | ₹66.72 - ₹99.50 |
| Volume | 1,112 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 14.52 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 1.82 |
| Price/Earning (TTM) | 17.32 |
| TTM EPS (₹) | 4.77 |
| P/E Ratio | 16.39 |
| Book Value(₹) | 2.30 |
| PAT Margin (%) | 5.27 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 16.02 |
| Trade Value ( ₹ in Lacs) | 0.92 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 1.82 |
| Price/Earning (TTM) | 17.32 |
| TTM EPS (₹) | 4.77 |
| P/E Ratio | 16.39 |
| Book Value(₹) | 2.30 |
| PAT Margin (%) | 5.27 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 16.02 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1858.83 | 6615.15 |
| Expenses | N/A | N/A |
| PBT | 99.2 | 610.05 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 76.12 | 473.52 |
About Anuh Pharma Ltd.
| Founded | 1960 |
|---|---|
| NSE Symbol | ANUHPHR |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,59,496.64 | 1,915.10 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,94,145.82 | 11,080.25 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,81,473.50 | 4,771.00 | 3,602.00 - 3,602.00 |
| Laurus Labs Ltd. | 1,28,054.00 | 2,370.00 | 917.95 - 917.95 |
| Lenskart Solutions Ltd. | 1,27,377.05 | 732.15 | 0.00 - 0.00 |
| Apollo Hospitals Enterprise Ltd. | 1,20,925.05 | 8,410.15 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,19,700.46 | 1,200.00 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,14,348.68 | 1,369.00 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,13,988.97 | 1,410.95 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,06,445.85 | 2,577.10 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Nov
8
2026
Posted on Nov 8th 2026
Divi's Laboratories - Quaterly Results
The sales surged to Rs. 36470.00 millions, up 37.11% for the September 2026 quarter as against Rs. 26600.00 millions during the corresponding quarter previous year.Handsome Net Profit growth of 63.79% reported above the corresponding previous quarter figure of Rs. 11400.00 millions to Rs. 6960.00 millions.The company reported a good operating profit of 16750.00 millions compared to 10410.00 millions of corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 36470.00 | 26600.00 | 37.11 | 66210.00 | 50170.00 | 31.97 | 103880.00 | 91980.00 | 12.94 |
| Other Income | 880.00 | 1460.00 | -39.73 | 1510.00 | 2650.00 | -43.02 | 5060.00 | 3520.00 | 43.75 |
| PBIDT | 16750.00 | 10410.00 | 60.90 | 29780.00 | 19030.00 | 56.49 | 39940.00 | 33310.00 | 19.90 |
| Interest | 130.00 | 80.00 | 62.50 | 190.00 | 110.00 | 72.73 | 230.00 | 10.00 | 2200.00 |
| PBDT | 16620.00 | 10330.00 | 60.89 | 29590.00 | 18920.00 | 56.40 | 38970.00 | 33300.00 | 17.03 |
| Depreciation | 1420.00 | 1130.00 | 25.66 | 2740.00 | 2250.00 | 21.78 | 4610.00 | 4010.00 | 14.96 |
| PBT | 15200.00 | 9200.00 | 65.22 | 26850.00 | 16670.00 | 61.07 | 34360.00 | 29290.00 | 17.31 |
| TAX | 3800.00 | 2240.00 | 69.64 | 6540.00 | 4140.00 | 57.97 | 8290.00 | 7200.00 | 15.14 |
| Deferred Tax | 100.00 | 40.00 | 150.00 | -60.00 | 30.00 | -300.00 | -400.00 | -730.00 | -45.21 |
| PAT | 11400.00 | 6960.00 | 63.79 | 20310.00 | 12530.00 | 62.09 | 26070.00 | 22090.00 | 18.02 |
| Equity | 530.00 | 530.00 | 0.00 | 530.00 | 530.00 | 0.00 | 530.00 | 530.00 | 0.00 |
| PBIDTM(%) | 45.93 | 39.14 | 17.36 | 44.98 | 37.93 | 18.58 | 38.45 | 36.21 | 6.17 |
Read More
Nov
7
2026
Posted on Nov 7th 2026
Chandra Bhagat Pharma informs about board meeting
Pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Chandra Bhagat Pharma has informed that a meeting of the Board of Directors of the company is scheduled to be held on Friday, 13th November, 2026 at 04:00 PM at the Registered Office of the Company, to consider and approve the Un-audited Financial Results of the Company for the half year ended 30th September, 2026. Further, in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company shall remain closed for all Directors, Key Managerial Personnel, Designated Employees and Connected Persons and shall reopen 48 hours after the declaration of the aforesaid financial results.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
7
2026
Posted on Nov 7th 2026
Phaarmasia informs about board meeting
Phaarmasia has informed that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 to consider and approve and take on record the un-audited financial results of the company for the quarter and half-year ended 30th September, 2026; To consider and take note of Limited Review Report for the quarter and half-year ended 30th September, 2026; To take note of Compliance Certificate Submitted by Chief Executive Officer and Chief Financial Officer in compliance with SEBI (LODR), 2015; To review and approve the related party transactions, if any; To take note of operations of the Company; To consider, discuss and approve any other matter with the permission of the Chair.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
7
2026
Posted on Nov 7th 2026
Gujarat Terce Laboratories informs about newspaper publication
Gujarat Terce Laboratories has enclosed extracts of the newspaper publication, in prescribed format, of the Unaudited Standalone Financial Results for the second quarter and half year ended 30 September 2026, approved by the Board of Directors of the Company at their Meeting held on Thursday, 5 November 2026 and published on Friday, 6 November 2026 in Gujarat Edition of the newspapers viz. Business Standard (English) and Jai Hind (Gujarati) (print and electronic version).
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
7
2026
Posted on Nov 7th 2026
Indoco Remedies informs about disclosures
Indoco Remedies has informed that the Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Suresh G Kare.
The above information is a part of company’s filings submitted to BSE.
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Anuh Pharma Ltd. is ₹82.79 as of 2026-11-08.
The market capitalisation of Anuh Pharma Ltd. is ₹827.55 as of 2026-11-08.
The 1-year return of Anuh Pharma Ltd. is -3.13% as of 2026-11-08.
The P/E ratio of Anuh Pharma Ltd. is 16.39 as of 2026-11-09.
The 52-week high and low of Anuh Pharma Ltd. are ₹99.50 and ₹67.00, respectively, as of 2026-11-08.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
